Sexton’s CT-5 is a new approach for product formulation and final fill of cell and gene therapy products.

As with any manufacturing process, cell therapy manufacturing can be boiled down to a sequence of unit operations. The process starts with an input, runs through operations A, B, C, D, etc., and it ends with an output, generally using separate systems that do not interact with each other. While the specific operations may be unique to cell therapy, the goal of standardizing the process flow is not different to other manufacturing processes and should be incorporated early in translational stages.

Read More